Irish Manufacturing Still Firm for Pfizer as Viagra Loses UK Patent

By Dan Stanton

- Last updated on GMT

Related tags Pfizer Erectile dysfunction

'Little Blue Pill' comes off patent in UK and Ireland
'Little Blue Pill' comes off patent in UK and Ireland
Pfizer says it remains committed to manufacturing in Ireland following the patent expiry of Viagra in UK last week.

Erectile dysfunction drug Viagra entered the market in 1998 and became a worldwide sensation and synonymous with the condition.

The drug is manufactured from Pfizer’s Ringaskiddy facility in Cork, Ireland, and - with Viagra losing exclusivity in the UK and Ireland last Friday - questions have been asked to whether the plant will suffer a similar fate to a nearby facility which was recently put up for sale as a direct result of patent expiration.

For now, however, “Ireland remains a key strategic location for Pfizer with many of [its] leading and new medicines manufactured here,”​ spokesperson Karen O’Keeffe told in-Pharmatechnologist.com.

A series of changes to the firm’s manufacturing operations have been implemented in Ireland, she said, “to reflect changing global demand and declining volumes following patent expiry of a number of key medicines.”

One-time bestseller Lipitor lost its US patent in November 2011 and Pfizer saw an immediate decline in sales and over-capacity at its Little Island manufacturing site – also in Cork - which led to an initial job loss​ and, last month, an announcement the plant was to be shuttered​.

Pfizer has also divested two other sites in Ireland in recent years, Shanbally​ (a third Cork facility) and Dun Laoghaire near Dublin​ that was sold to Amgen.

However, O’Keeffe said “Pfizer is exploring the potential for future investment in operations in Ireland”​ adding that it had recently invested $200m (€152m) at its Grange Castle biotech plant in Dublin, as well having four of its new medicines manufactured for the global market from Irish facilities.

Viagra Production

A Pfizer source told The Irish Times that end of the patent was “not a huge concern”​ at the site, as Viagra “was never in constant production,”​ and even at its height represented only 15 percent of API manufacture at one of the plants at Ringaskiddy.

“What we would have was two production campaigns a year each lasting a couple of months where we would makes tonnes of Sildenafil to be sent to a central store in Brussels and drawn on as required,”​ the source told the paper.

Any casualness at Ringaskiddy may also be down to the US patent for ‘the little blue pill’ not expiring until 2020, after gaining an extension on the original March 2010 date following a lawsuit with generic manufacturer Teva.

Teva, in the meantime, has announced it plans to launch its generic Viagra, Sildenafil, in countries where the patent has expired, according to Israeli publication Globes​. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Webinars

Headlines